Outlook of Cell Gene Therapies Development and Approval from Quality and Regulatory Perspective
Therapeutic Innovation & Regulatory Science · 2026
DOI: 10.1007/s43441-026-00920-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2026. Verfasst von Carolina Iglesias-Lopez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Dublin, Ireland. Hauptthemen laut MEDLINE: Genetic Therapy, Cell- and Tissue-Based Therapy, Drug Approval. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitat Autònoma de Barcelona.
Abstract (Originalsprache)
Background
Cell and gene therapies represent a transformative advance in modern medicine but pose major quality and regulatory challenges. The complexity of manufacturing, product comparability, and potency assessment often limits dossier robustness and delays approval.
Methods
A systematic review was conducted on cell gene therapies approved in the European Union (EU) and the United States (US) up to December 2024. Publicly available regulatory data from EMA and FDA sources were analyzed to identify key regulatory milestones and quality issues during marketing authorization.
Results
Fourteen cell gene therapies were approved (12 in the US, 11 in the EU). All received orphan designation, and over 80% benefited from expedited development pathways. The most frequent quality objections concerned manufacturing comparability, potency assay validation, specifications, and stability data. Although regulatory support mechanisms accelerated submissions, they did not consistently translate into higher-quality dossiers. The FDA follows a data-driven approach, while the EMA takes a broader, science-based view and continuous improvement.
Conclusion
Ensuring robust quality data packages remains the main bottleneck in cell gene therapy development. Early integration of quality-by-design principles, comprehensive comparability assessments, and validated potency assays are essential to strengthen regulatory submissions. Continuous dialogue with regulatory agencies and harmonization between regions are key to accelerating patient access while maintaining product quality and consistency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gilead Sciences, Dublin, Ireland.
- Pharmacology, Therapeutics and Toxicology Department, Universitat Autònoma de Barcelona, Barcelona, Spain. antoni.vallano@uab.cat.
- Medicines Area, Catalan Health Service (CatSalut), Barcelona, Spain. antoni.vallano@uab.cat.
- Catalan Institute of Health (ICS), Barcelona, Spain. antoni.vallano@uab.cat.
- Pharmacology, Therapeutics and Toxicology Department, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Clinical Pharmacology Service, Vall Hebron University Hospital, Barcelona, Spain.
Förderung
- Universitat Autònoma de Barcelona
Zitieren
APA
Iglesias-Lopez, C., Vallano, A., & Agustí, A. (2026). Outlook of Cell Gene Therapies Development and Approval from Quality and Regulatory Perspective. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-026-00920-4
Vancouver
Iglesias-Lopez C, Vallano A, Agustí A. Outlook of Cell Gene Therapies Development and Approval from Quality and Regulatory Perspective. Therapeutic Innovation & Regulatory Science. 2026. doi:10.1007/s43441-026-00920-4
BibTeX
@article{IglesiasLopez2026,
author = {Iglesias-Lopez, Carolina and Vallano, Antonio and Agustí, Antònia},
title = {Outlook of Cell Gene Therapies Development and Approval from Quality and Regulatory Perspective},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2026},
doi = {10.1007/s43441-026-00920-4}
}
EUVIMED